anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The body conformations of 262 adult Ganjam goats were subjected to principal component analysis (PCA) with 11 morphometric variables. The results were then used to predict the mature body weight of the goats. Most of the traits were positively correlated, and the correlations were statistically significant. The three main components that the PCA recovered explained 76.12% of the variation in body morphometry overall. The first component accounted for approximately 54.74% of the overall variation and described almost all the traits except ear length and tail length, as indicated by high component loadings. The second component accounted for approximately 11.48% of the variation, mostly accounting for the variation in tail length. The principal component accounted for 9.89% and mostly explained the variation in ear length. The communalities ranged between 0.557 (horn length) and 0.848 (chest circumference) for the first three extracted components. The highest percentage of variability in chest girth was explained by the first three principal components, whereas it was the lowest for the horn length. In the context of predicting body weight through stepwise regression analysis, nine primary variables accounted for 57.3% of the total variance in body weight. Conversely, utilizing the first principal component alongside six additional principal components as independent variables resulted in capturing 56.3% of the variation in the adult live weight of goats while maintaining model comparability with other pertinent parameters. PCA was used efficiently for body weight prediction from major morphometric traits of Ganjam goats addressing the multicollinearity issue.
Diazepam is a medication that is used for the treatment of seizures. It was approved by the Food and Drug Administration (FDA) for use in the United States and is currently sold as Valium® tablets, Diazepam Injection and Diastat® rectal gel.

This study will evaluate two intranasal (nasal spray) formulations of diazepam which will be supplied by Neurelis, Inc. The purpose of this clinical research study is to assess the bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and injectable diazepam after intravenous (I.V.) administration. "Bioavailability" is a measure of how much drug is absorbed and present in the blood. "Pharmacokinetics" means to study the way a drug enters and leaves the blood and tissues over time
<P>PROBLEM TO BE SOLVED: To provide a cosmetic and a skin preparation for external use blended with a poly-γ-L-glutamic acid and/or its salt and an antiaging agent, without having stickiness and excellent in refreshing feeling.  <P>SOLUTION: This cosmetic composition without having the stickiness and excellent in the refreshing feeling contains the poly-γ-L-glutamic acid and/or its salt and the antiaging agent, while maintaining the effect of the antiaging agent. The antiaging agent may be an anti-inflammatory agent and/or an antioxidant. Further, the cosmetic composition may contain a humectant, an ultraviolet light absorbent and/or an anti-bacterial agent. The cosmetic composition can be utilized as a cosmetic, quasi-drug, medical supply or medicine.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention discloses a codon-optimized porcine lambda 3 interferon coding gene and application thereof in preparation of porcine lambda 3 interferon. In particular discloses a codon-optimized porcine lambda 3 interferon gene PoIFN lambda 3-MD and a method for preparing recombinant porcine lambda 3 interferon by using the gene. The expression capacity of the optimized gene PoIFN lambda 3-MD in host bacteria is far higher than that of the unoptimized gene PoIFN lambda 3-WT. The optimized PoIFN lambda 3-MD is inserted into a multiple cloning site of a vector pET30a (+) to obtain a recombinant plasmid, and the recombinant plasmid is introduced into escherichia coli to obtain a recombinant bacterium. The recombinant strain can be used for preparing a large amount of high-activity recombinant porcine lambda 3 interferon protein through induction culture. The gene, the recombinant plasmid and the recombinant bacterium provided by the invention have great economic value for the production of the recombinant porcine lambda 3 interferon, and also have great application value and wide application prospect for the live pig breeding industry.
The Investigators have carefully considered the over-time assessment factor in this design, and have chosen two follow-up assessments over a 9 month-period because a) our prior WayToServe® trials have shown that an immediate post-training assessment will document intervention effects when training effects are at optimum levels immediately after the training; b) the sustained effect of WTS-E needs to be demonstrated to show long-term not just short-term impact (9 months being between our previous 6-month and 1-year follow-ups). Finally, c) all follow-ups can be completed within the approximately 2-year period of a Phase II project. The immediate post-training assessment will occur for both arms of the design, one month after premises in the intervention arm are given access to WTS-E.
Some embodiments described herein are directed to a universal health platform that may efficiently provide sophisticated health data processing and treatment recommendations. In some embodiments, the platform may be configured to allow a user (e.g. a patient or health professional) to input or import a vast and varied collection of data including health, medical, lifestyle, historical, and other relevant data. The platform may be configured to process this data through a multifaceted and dynamically updated decision-making protocol to create a personalized patient report. In some embodiments, the personalized patient report may comprise various medications, treatment, preventative, health, lifestyle, and behavioral recommendations and/or plans. In some embodiments, the data input and personalized patient report features are communicated to a user through a dynamic user interface configured to automatically update and adjust based on newly inputted data or user selection and/or rejection of recommendations in the personalized patient report.
Immune checkpoint blockade therapy is based on the inhibition of the tumor-mediated suppression of anticancer immune responses. However, the efficacy and effectiveness of said therapy vary greatly across individual patients and among different tumor types. A substantial unmet need is thus to identify novel targets that can enhance the therapeutic efficacy of the immune checkpoint blockade therapy. S1P is produced by sphingosine kinases (i.e. SK1 and SK2) that catalyze the phosphorylation of sphingosine to S1P. SK2 inhibitors were described as suitable for the treatment of cancer. However the role of SK2 in the immune tumor microenvironment has never been investigated. The inventors now showed that genetic deletion of SPHK2 leads to a delay in the melanoma tumor growth and an increase in tumor-infiltrating effector lymphocytes. In particular the increase of tumor-infiltrating effector lymphocytes in the tumor is associated with a decrease in the amount of tumor-infiltrating myeloid-derived suppressor cells. Moreover, the combination of SPHK2 deficiency with immune-checkpoint blockade leads to tumor rejection and increases survival rate. Accordingly, the present invention relates to use of SK2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer.
PURPOSE:To obtain the subject substance having high antimycotic activity and useful for pharmaceuticals, agricultural chemicals, etc., by culturing a bacterial strain belonging to genus Pseudomonas and capable of producing an antimycotic substance Y1-HU1 in a culture medium. CONSTITUTION:Pseudomonas sp. Y1-HU1 strain having the following bacteriological properties was obtained by separating and searching the soil collected in Wakayama city. Size of cell; 1-5mum; having flagella and mobility; activity, unable to hydrolyze starch and utilizing citric acid; growth temperature, 25-40 deg.C; negative to Gram-staining; positive to oxidase; etc. The strain is aerobically cultured in a potato dextrose medium containing leached potato liquid at 10-40 deg.C for 2-5 days. The cultured product is extracted with chloroform, etc., and purified to obtain the objective antimycotic substance Y1-HU1 having the following physical and chemical properties. Molecular weight, 461; ultraviolet absorption spectrum, exhibits absorption peak at 270nm in methanol; solubility, easily soluble in chloroform, soluble in methanol and insoluble in n-hexane; color, white; etc.
INTRODUCTION: The incidence of brain tumors has increased in elderly population overtime. Their eligibility to a major surgery remains a questionable subject. This study evaluated prognostic factors and 30-days morbidity and mortality in octogenarian population who underwent craniotomy for resection of brain tumor.
MATERIALS AND METHODS: A total of 154 patients were divided into two different groups: patients above 80 years old and patients below 65 years old. In both groups, patients were stratified based on diagnosis with benign tumors [meningioma] and malignant tumors [high-grade gliomas and metastases]. Multivariable logistic regression model with backward elimination method was utilized to identify the independent risk factors for 30-days readmission and post-operative complications.
RESULTS: The analysis revealed no significant difference in 30-day readmission (p = 0.7329), 30-day mortality (0.6854) or in post-operative complication (p = 0.3291) between age ≥ 80 and age ≤ 65 groups. A longer length of stay (LOS) was observed in the older patients (p = 0.0479). There was a significant difference in the pre-post KPS between the two groups (p < 0.0001). ASA (p = 0.0315) and KPS (p = 0.071) were found as important prognostic factors associated with post-operative mortality in both groups.
CONCLUSION: Octogenarians can withstand craniotomy without any significant increase in 30-day readmission, 30-day mortality and post-operative complications as compared to patients younger than age 65. The ASA score (>3) and/or KPS (<70) were the most important prognostic factors for 30-days readmission and mortality.
The quest for efficient hemostatic agents in emergency medicine is critical, particularly for managing massive hemorrhages in dynamic and high-pressure wound environments. Traditional self-gelling powders, while beneficial due to their ease of application and rapid action, fall short in such challenging conditions. To bridge this gap, the research introduces a novel self-gelling powder that combines ultrafast covalent gelation and robust wet adhesion, presenting a significant advancement in acute hemorrhage control. This ternary system comprises ε-polylysine (ε-PLL) and 4-arm polyethylene glycol succinyl succinate (4-arm-PEG-NHS) forming the hydrogel framework. Na2HPO4 functions as the "H+ sucker" to expedite the amidation reaction, slashing gelation time to under 10 s, crucial for immediate blood loss restriction. Moreover, PEG chains' hydrophilicity facilitates efficient absorption of interfacial blood, increasing the generated hydrogel's cross-linking density and strengthens its tissue bonding, thereby resulting in excellent mechanical and wet adhesion properties. In vitro experiments reveal the optimized formulation's exceptional tissue compliance, procoagulant activity, biocompatibility and antibacterial efficacy. In porcine models of heart injuries and arterial punctures, it outperforms commercial hemostatic agent Celox, confirming its rapid and effective hemostasis. Conclusively, this study presents a transformative approach to hemostasis, offering a reliable and potent solution for the emergency management of massive hemorrhage.
Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
Eligible patients are randomly assigned to receive intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy of docetaxel plus cisplatin or cisplatin alone. IMRT is delivered with a total dose of 68 Gy or higher in 33 fractions to the primary tumor. Concurrent chemotherapy in the experimental arm consists of docetaxel 60 mg/m², D1 and cisplatin 25 mg/m², D1-3 every 3 weeks for 3 cycles. Concurrent chemotherapy in the control arm consists of cisplatin 100 mg/m², D1 every 3 weeks for 3 cycles.The primary endpoint is overall survival (OS), defined as time from randomization to the day of death from any cause. Secondary end points include failure-free survival (FFS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and the incidence of grade 3 or higher acute toxicities. All efficacy analyses are conducted in the intention-to-treat population, and the safety population include only patients who receive their randomly assigned treatment.
The present invention relates to bacterium prodigiosum polysaccharide for nose drops and relates to improvement on a bacterium prodigiosum polysaccharide dosage form. The present invention is formed by mixing and dissolving 200 to 400 active units of bacterium prodigiosum polysaccharide and 3.0 to 5.0 ml of solution. Via intranasal administration, compared with muscle administration, the present invention has the advantages that the administration is convenient, and guided by medical staff, and a patient can use the bacterium prodigiosum polysaccharide by himself so as to lighten the burdens of doctors and patients. Intranasal administration provides convenience for increased administration, increases the curative effect, has no pain, discomfortable feeling or human body's adverse reaction, and can be accepted by eligible patients. According to the dosage, the bacterium prodigiosum polysaccharide can run out because of the intranasal administration way, and therefore, residual liquid medicine can not be wasted. Because of a large area, rapid and complete absorption and high biological availability, intranasal administration strengthens the medicine effect. Compared with muscle administration, intranasal administration has reduced total cost and is easy for wide clinical application.
SCA is an inherited blood disorder in which the body makes sickle-shaped red blood cells that contain abnormal hemoglobin. The sickled cells block blood flow in the vessels that lead to limbs and organs. This can cause pain, serious infections, and organ damage. The BABY HUG study (NCT00006400) is examining whether the medication hydroxyurea can prevent organ damage, especially in the spleen and kidneys, in children with SCA. This study is a follow-up study to the BABY HUG study and will enroll children who have participated in the BABY HUG study. The purpose of this study is to examine the long-term effects of using hydroxyurea as a treatment for SCA, including both the risks and benefits. Study researchers will also investigate the optimal age to begin treatment with hydroxyurea in children with SCA.

This study will enroll children between 2 and 7 years old who participated in the BABY HUG study. Hydroxyurea will not be provided to participants as part of this study, but participants may receive the medication from their own doctors. Parents of participants can choose for their child to participate in this study in one of two ways-by enrolling in either a passive follow-up group or an active follow-up group. For participants in the passive follow-up group, study researchers will review participants' medical records every 6 months, in addition to reviewing brain ultrasound tests and computed tomography (CT) or magnetic resonance imaging (MRI) scans, if completed. Participants will have a blood and urine collection at baseline and Year 4 (or at the end of the study, whichever comes first). Participants in the active follow-up group will take part in the same study procedures as participants in the passive follow-up group. In addition, at Year 2, participants in this group will undergo an additional blood and urine collection, a scanning procedure to obtain images of the liver and spleen, a kidney test, neuropsychological testing, and an ultrasound imaging test to evaluate liver and spleen size.
Patients will receive 50 ml of Bupivacaine 0.25% (125mg) diluted in 100 ml of normal saline. The drug will be injected intraperitoneally through trocars at the end of the surgery.
This is a pilot study evaluating the product, 3M™ Cavilon™ Advanced Skin Protectant, for the management of skin around an ostomy, drain and/or fistula. All subjects will receive the product for up to 14 days. The primary site must have red skin with breakdown (i.e. skin erosion and denudation or denudation of skin alone). Secondary sites can have red skin with or without breakdown. Product will be applied twice/week or more frequently if additional applications are needed due to leakage, skin irritation or standard of care. Skin assessments (including photography) will be completed at baseline and at all follow-up visits.
Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
<P>PROBLEM TO BE SOLVED: To implement a high performance medical text search by automatically selecting an appropriate search method in accordance with a search word.  <P>SOLUTION: When a search word input part 1 acquires a search word, a search method decision part 2 refers to a determinative character list holding part 4 to determine whether or not the search word contains any determinative characters. If the search word contains any determinative characters, an N-gram method (N=1) is designated as a text search method. If the search word does not contain any determinative characters, on the other hand, a morphological analysis dictionary holding part 5 is referred to for determining whether or not a morphological analysis dictionary has an entry for the search word. If an entry for the search word is found, a morphological analysis method is designated, or if an entry for the search word is not found, an N-gram method (N is the number of characters in the search word) is designated.  <P>COPYRIGHT: (C)2010,JPO&INPIT
BACKGROUND AND AIMS: A single-nation study reported that pretreatment HBV viral load is associated with on-treatment risk of HCC in patients who are HBeAg-positive without cirrhosis and with chronic hepatitis B initiating antiviral treatment. We aimed to validate the association between baseline HBV viral load and on-treatment HCC risk in a larger, multinational cohort.
APPROACH AND RESULTS: Using a multinational cohort from Korea, Hong Kong, and Taiwan involving 7545 adult patients with HBeAg-positive, without cirrhosis and with chronic hepatitis B who started entecavir or tenofovir treatment with baseline HBV viral load ≥5.00 log 10 IU/mL, HCC risk was estimated by baseline viral load. HBV viral load was analyzed as a categorical variable. During continuous antiviral treatment (median, 4.28 y), HCC developed in 200 patients (incidence rate, 0.61 per 100 person-years). Baseline HBV DNA level was independently associated with on-treatment HCC risk in a nonlinear pattern. HCC risk was lowest with the highest baseline viral load (≥8.00 log 10 IU/mL; incidence rate, 0.10 per 100 person-years), but increased sharply as baseline viral load decreased. The adjusted HCC risk was 8.05 times higher (95% CI, 3.34-19.35) with baseline viral load ≥6.00 and <7.00 log 10 IU/mL (incidence rate, 1.38 per 100 person-years) compared with high (≥8.00 log 10 IU/mL) baseline viral load ( p <0.001).
CONCLUSIONS: In a multinational cohort of adult patients with HBeAg-positive without cirrhosis and with chronic hepatitis B, baseline HBV viral load was significantly associated with HCC risk despite antiviral treatment. Patients with the highest viral load who initiated treatment had the lowest long-term risk of HCC development.
IPT is a short-term psychotherapy aiming to ameliorate both physical and psychosocial distress. It emanates from a multidirectional and dynamic relationship among body, mind, and environment irrespective of causality. In a multi-component approach, other elements are integrated into it, such as cognitive-behavioral and psychodynamic techniques, psychoeducation and body-oriented techniques. The IPT intervention tailored to SVD will be delivered for 16 weeks in a manualised setting with one group session per week (à 90 minutes) and one additional booster session three months after the end of the therapy. The group psychotherapy is on a 6-8:1 basis and will be conducted by a psychotherapist trained on the basis of the manual and under regular clinical supervision.
BELBUCA has not been evaluated in patients with severe hepatic impairment.

The effects of hepatic impairment on the pharmacokinetics of buprenorphine were evaluated in a pharmacokinetic study. Buprenorphine is extensively metabolized in the liver and buprenorphine plasma levels were found to be higher and the half-life was found to be longer in subjects with moderate and severe hepatic impairment, but not in subjects with mild hepatic impairment.

Given that increased buprenorphine plasma levels are associated with a greater risk of toxicity and overdose, a dosage reduction in patients with severe hepatic impairment (i.e., Child-Pugh C) is recommended [see Dosage and Administration (2.6)]. Regularly evaluate patients with severe hepatic impairment for signs and symptoms of overdose. A dosage reduction in patients with moderate hepatic impairment (Child-Pugh B) is not needed; however, regularly evaluate these patients for signs and symptoms of toxicity or overdose. A dosage reduction in patients with mild hepatic impairment (Child-Pugh A) is not needed [see Dosage and Administration (2.6), Warnings and Precautions (5.19), Clinical Pharmacology (12.3)].
Provided herein are methods for identifying and treating a malignancy in a patient. Aspects of the described methods are performed through use of a computing device. The method comprises receiving at the computing device a plurality of spectra acquired from a corresponding plurality of aliquots containing a biophysiological carrier protein. At least one of a concentration of a spin probe and a concentration of a polar reagent varies between the aliquots. The computing device then determines biophysical parameters based on the received spectra and applies at least parts of the received spectra and the biophysical parameters as an input to a trained logistic regression model. The logistic regression model trained to determine a probability of applied input parameters relating to one or more of a plurality of predetermined diseases and/or disease localisations. The trained model is used to determine a probability of the input parameters relating to one or more of said predetermined diseases and/or disease localisations and outputs a result of the determination, which can be used to determine and then provide proper therapeutic treatments.
Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.